Landen Pharmachem
0821.924.352 · rovalta.com · 26/09/2026
NORMAL SITUATION
Landen Pharmachem
Company — Normal situation.
Financial year 2021 · Closed on 30/09/2021
Net result-964,1 €+94,3 %over 1 year
Gross margin-617,5 €+90,5 %over 1 year
Equity-964,9 k €-0,1 %over 1 year
Overview
Identity
Source · BCE/KBOLanden Pharmachem is a company registered in Belgium.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0821.924.352
- Legal form
- Public limited company
- Contributed capital
- 600 000,00 €
- Latest accounts
- 30/09/2021
Joint committees (2)
- 116
- 207
Financials
Source · NBB, 11 filingsTrend over 11 financial years
| 2021 | 2020 | 2019 | 2018 | 2017 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -617,5 € | +90.5% | -6,5 k € | -96.3% | -3,3 k € | +50.4% | -6,7 k € | -639% | -900 € |
| EBITDA | -617,5 € | +90.5% | -6,5 k € | -131% | 20,8 k € | +413% | -6,7 k € | -639% | -900 € |
| Operating result | -617,5 € | +90.5% | -6,5 k € | -131% | 20,8 k € | +413% | -6,7 k € | -639% | -900 € |
| Net result | -964,1 € | +94.3% | -17 k € | -176% | 22,4 k € | +445% | -6,5 k € | +82.6% | -37,4 k € |
| Balance sheet | |||||||||
| Equity | -964,9 k € | -0.1% | -963,9 k € | -1.8% | -946,9 k € | +2.3% | -969,3 k € | -0.7% | -962,8 k € |
| Total assets | 688,5 k € | -0.1% | 689,5 k € | -2.7% | 708,9 k € | -0.1% | 709,8 k € | -0.9% | 716,3 k € |
| Cash | 688,5 k € | -0.1% | 689,3 k € | -2.7% | 708,5 k € | -0.1% | 709,6 k € | -0.9% | 716,1 k € |
| Debts | 983,9 k € | 0.0% | 983,9 k € | -0.2% | 986,3 k € | +17.6% | 838,5 k € | 0.0% | 838,5 k € |
| Other | |||||||||
| Workforce | – | – | – | – | – | ||||
Board of directors
Source · NBB, accounts to 30/09/20211 active · 4 ended
Active mandates
Karl Vanstipelen
ActiveEnded mandates
Jan Hoflack
EndedJan Hoflack
EndedJan Van Roy
EndedJan Van Roy
EndedFinancials
Full financial information
Source · NBB| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/10/2020 | 01/10/2019 | 01/10/2018 | 01/10/2017 | 01/10/2016 | 01/10/2015 |
| Closing of the financial year | 30/09/2021 | 30/09/2020 | 30/09/2019 | 30/09/2018 | 30/09/2017 | 30/09/2016 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 29/04/2022 | 29/01/2021 | 17/04/2020 | 05/12/2019 | 05/12/2019 | 05/12/2019 |
| General meeting | – | 01/01/9999 | 01/01/9999 | 01/01/9999 | 01/01/9999 | 01/01/9999 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 11 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 30/09/2021 | — | 29/04/2022 | Dutch | |
| Abridged model | 30/09/2020 | 01/01/9999 | 29/01/2021 | Dutch | |
| Abridged model | 30/09/2019 | 01/01/9999 | 17/04/2020 | Dutch | |
| Abridged model | 30/09/2018 | 01/01/9999 | 05/12/2019 | Dutch | |
| Abridged model | 30/09/2017 | 01/01/9999 | 05/12/2019 | Dutch | |
| Abridged model | 30/09/2016 | 01/01/9999 | 05/12/2019 | Dutch | |
| Abridged model | 30/09/2015 | 01/01/9999 | 05/12/2019 | Dutch | |
| Abridged model | 30/09/2014 | 01/01/9999 | 05/12/2019 | Dutch | |
| Abridged model | 30/09/2013 | 01/01/9999 | 08/08/2014 | Dutch | |
| Abridged model | 30/09/2012 | 01/01/9999 | 29/03/2013 | Dutch | |
| Abridged model | 30/09/2011 | 19/12/2011 | 19/01/2012 | Dutch |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 30/09/20211 active · 4 ended
Active mandates
Karl Vanstipelen
ActiveEnded mandates
Jan Hoflack
EndedJan Hoflack
EndedJan Van Roy
EndedJan Van Roy
EndedOwnership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Dissolution05/01/2023RUBRIEK EINDE (STOPZETTING, INTREKKING STOPZETTING, NIETIGHEID, GER. AK., GERECHTELIJKE REORGANISATIE, ENZ...
- Dissolution19/02/2013RUBRIEK EINDE (STOPZETTING, INTREKKING STOPZETTING, NIETIGHEID, GER. AK., GERECHTELIJKE REORGANISATIE, ENZ... - ONTSLAGEN - BENOEMINGEN
- Other14/01/2010RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2021Annual accounts 2021-964,1 €↑
- 2020Annual accounts 2020-17 k €↓
- 2019Annual accounts 201922,4 k €↑
- 2018Annual accounts 2018-6,5 k €↑
- 2017Annual accounts 2017-37,4 k €↓
- 2016Annual accounts 2016216,7 k €↑
- 2015Annual accounts 2015-153,3 k €↓
- 2014Annual accounts 2014172,5 k €↑
- 2013Annual accounts 2013-529,8 k €↑
- 2012Annual accounts 2012-1,2 M €↓
- 2011Annual accounts 2011-45,5 k €